Table V.
Tumor protection in outbred New Zealand White rabbits challenged with CRPV DNA containing the HPV16E7 82-90 epitope inserted in the E7 gene after three immunizations with either the HPV16E7/82-90 epitope vaccine or the control vector vaccine.
| Rabbits | Vaccine | Challenged Sites | Protection Ratea (%) | |
|---|---|---|---|---|
| 1 | HLA-A2.1 (N = 3) | E7 Epitope | 18 | 18/18 (100%)b,c,d |
| 2 | Control (N = 3) | E7 Epitope | 18 | 1/18 (6%) |
| 3 | HLA-A2.1 (N = 4) | Vector | 24 | 7/24 (26%) |
| 4 | Control (N = 3) | Vector | 18 | 5/18 (28%) |
a
Protection rate, papilloma-free sites/challenge sites (six sites/each construct/each rabbit);
b
p = 0.0009,
c
p = 0.025,
d
p = 0.054 vs group 2, group 3, and group 4, respectively, Fisher’s exact test.